Lantern Pharma (LTRN) Other Working Capital Changes (2022 - 2026)
Lantern Pharma's (LTRN) quarterly Other Working Capital Changes came in at -$19463.0 in Q1 2026, up 60.06% YoY from -$12160.1 in Q1 2025, and up 52.44% on a QoQ basis from -$40922.0 in Q4 2025.
Lantern Pharma (LTRN) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 5 years of Other Working Capital Changes data on file, last reported at -$19463.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 60.06% year-over-year to -$19463.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$161362.0 (up 12.09% YoY) and the FY2025 annual result came in at -$190625.0, down 8.49% from the prior year.
- Other Working Capital Changes climbed to -$19463.0 in Q1 2026, from -$40922.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $1.1 million in Q2 2022 to a low of -$901017.0 in Q1 2024.
- A 5-year average of -$73568.6 and a median of -$133375.0 in 2025 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2025 — Other Working Capital Changes dropped 19.17% — and 2026, when it surged 60.06%.
- Tracing LTRN's Other Working Capital Changes over 5 years: stood at -$40051.0 in 2022, then retreated by 0.02% to -$40058.0 in 2023, then declined by 18.8% to -$47587.0 in 2024, then increased by 14.01% to -$40922.0 in 2025, then surged by 52.44% to -$19463.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$19463.0 (Q1 2026), -$40922.0 (Q4 2025), and -$51085.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Lantern Pharma | 25.99 Mn | 25.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19,463.00 |
| Mar 31, 2026 | -19,463.00 |
| Mar 31, 2026 | -19,463.00 |
| Dec 31, 2025 | -40,922.00 |
| Dec 31, 2025 | -40,922.00 |
| Dec 31, 2025 | -40,922.00 |
| Sep 30, 2025 | -51,085.00 |
| Sep 30, 2025 | -51,085.00 |
| Sep 30, 2025 | -51,085.00 |
| Jun 30, 2025 | -49,892.00 |
| Jun 30, 2025 | -49,892.00 |
| Jun 30, 2025 | -49,892.00 |
| Mar 31, 2025 | -48,726.00 |
| Mar 31, 2025 | -48,726.00 |
| Mar 31, 2025 | -48,726.00 |
| Dec 31, 2024 | -47,587.00 |
| Dec 31, 2024 | -47,587.00 |
| Dec 31, 2024 | -47,587.00 |
| Sep 30, 2024 | -44,511.00 |
| Sep 30, 2024 | -44,511.00 |